Antimicrobial resistance poses an ever-increasing healthcare threat, with pathogens evolving resistance faster than novel therapies are being developed. ESKAPE pathogens are just six of the many bacteria which have acquired the ability to escape the actions of current antibiotics.
CDI often occurs after long-term treatment with broad-spectrum antibiotics, which can drastically alter the normal bowel flora and decrease healthy bacterial populations, providing a breeding ground for pathogenic bacteria. The most common treatment for CDI, vancomycin, is also an antibiotic. Using an antibiotic to treat a disease caused by antibiotics is problematic, and recurrence rates for C. diff infections can exceed 60%. As recurrence is usually more difficult to treat than initial infections, there is an unmet medical need for alternative therapeutics. Fecal microbiota transplantation (FMT) is one such alternative.
Superbugs, or multi-drug resistant (MDR) bacteria, are bacteria that cannot be killed using two or more antibiotics. As antimicrobial resistance increases, scientists are looking to other ways of fighting infection. There is growing support for bacteriophages as a promising new therapeutic against super bugs.
Our experienced and knowledgeable staff will help you navigate the preclinical period of your research project from beginning to end. Check out the infographic for what to expect at every step along the way.